Shares of Pacific Biosciences of California (PACB) surged 5.22% on Friday, November 11th, following updates from analysts at Piper Sandler and Scotiabank.
Piper Sandler raised their price target on PACB to $2.50 from $2, while maintaining a Neutral rating. The firm cited the company's recent quarterly results as the reason for the increased target price.
Meanwhile, Scotiabank lowered their price target on PACB to $6 from $7, but kept an Outperform rating on the stock. The bank's analyst, Sung Ji Nam, revised their fiscal year 2024 estimates for the company, leading to the target price adjustment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments